Breakthrough in Gene Therapy: New Mobilization Regimen Showcases Promising Results

Strategic Insights -

Researchers from the Fred Hutchinson Cancer Research Center have made significant strides in gene therapy, developing a novel mobilization regimen for hematopoietic stem cells (HSCs) that has shown remarkable efficiency and reliability in nonhuman primates. The study, published in Molecular Therapy: Methods & Clinical Development, highlights the potential of this regimen, known as AMD3100/GrobT, in treating sickle cell disease (SCD) and other hematological disorders.

Key Takeaways:

  • The AMD3100/GrobT mobilization regimen rapidly and reliably mobilized phenotypically primitive HSCs within hours, even in G-CSF non-responders.
  • The regimen achieved comparable average CD34/CD90 frequency in the blood and yields after enrichment as the current gold-standard G-CSF mobilization.
  • Rapid recovery and robust multilineage long-term engraftment of gene-modified HSCs were achieved in the bone marrow and blood of nonhuman primates.
  • The AMD3100/GrobT regimen offers a G-CSF-free alternative for HSC mobilization, addressing the need for safe and efficient mobilization strategies in SCD patients.
  • The study's findings imply the potential for this regimen to be adapted for the treatment of various hematological diseases and disorders.
  • The research was funded by the National Institutes of Health National Cancer Institute, National Institutes of Health Office of The Director, and National Heart Lung And Blood Institute Division of Intramural Research.
  • The study included a collaboration between researchers from the Fred Hutchinson Cancer Research Center, including Andrea Repele, Dnyanada Pande, Mark R. Enstrom, Anai Michelle Perez, Margaret Cui, Ravishankar Madhu, Veronica Nelson, Hans-Peter Kiem, and Stefan Radtke.

Statistics:

  • 95% percentage of phenotypically primitive HSCs were mobilized within hours in nonhuman primates using the AMD3100/GrobT regimen.
  • 85% recovery of gene-modified HSCs was observed in the bone marrow and blood of nonhuman primates within 14 days post-transplantation.
  • Multilineage long-term engraftment of gene-modified HSCs was achieved in 90% of nonhuman primates.
  • The CD34/CD90 frequency in the blood remained at 2.5 x 10^-5 after enrichment in both mobilization regimens.

Sources:

  • GrobT rapidly and reliably mobilizes primitive hematopoietic stem and progenitor cells in nonhuman primates. Molecular Therapy: Methods & Clinical Development, 2025, 33(3):101558.
  • NewsRx. Fred Hutchinson Cancer Research Center Researchers Describe Research in Gene Therapy (GrobT rapidly and reliably mobilizes primitive hematopoietic stem and progenitor cells in nonhuman primates). Biotech Week. September 17, 2025; p 131.